Mairead McGrattan1, Heather E Barry1, Cristín Ryan2, Janine A Cooper3, A Peter Passmore4,5, A Louise Robinson6, Gerard J Molloy7, Carmel M Darcy8, Hilary Buchanan9, Carmel M Hughes1. 1. School of Pharmacy, Queen's University Belfast, Medical Biology Centre, Belfast, UK. 2. The School of Pharmacy and Pharmaceutical Sciences, Panoz Institute, Trinity College Dublin, Dublin 2, Ireland. 3. Bamford Centre for Mental Health and Wellbeing, Ulster University, Jordanstown, UK. 4. Centre for Public Health, Institute of Clinical Sciences, Queen's University Belfast, Block B, Royal Victoria Hosptial, Belfast, UK. 5. Belfast Health and Social Care Trust, Belfast, UK. 6. Newcastle University, Institute for Ageing and Institute for Health and Society, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, UK. 7. School of Psychology, National University of Ireland, Galway, Ireland. 8. Western Health and for Social Care Trust, Londonderry, UK. 9. Belfast, UK.
Abstract
BACKGROUND: people with dementia (PWD), and their carers, face challenges with medicines management activities. As interventions to support medicines management for PWD are developed, consideration must be given to the outcomes chosen to measure their effectiveness. A Core Outcome Set (COS) is a minimum set of outcomes to be measured in all trials in a particular clinical area, which seeks to reduce heterogeneity of outcome reporting across trials. OBJECTIVE: to develop a COS for trials assessing the effectiveness of medicines management interventions for PWD in primary care. METHODS: a comprehensive list of outcomes was compiled through a systematic review and semi-structured interviews with PWD (n = 18), their carers (n = 15), community pharmacists (n = 15) and general practitioners (n = 15). These outcomes were rated by a Delphi panel (n = 52) on a nine-point Likert scale from 1 (limited importance) to 9 (critical) during three sequential rounds of questionnaire distribution. The Delphi panel comprised participants with expertise in dementia and medicines management, including academics and healthcare professionals. An outcome was eligible for inclusion in the COS if ≥70% of participants rated it critical and <15% of participants rated it of limited importance. RESULTS: twenty-nine outcomes identified from the systematic review and stakeholder interviews were presented to the Delphi panel. Consensus was reached on 21 outcomes, of which the 7 most highly rated were recommended for inclusion in the COS. CONCLUSION: this study used robust methodology to develop a COS for medicines management interventions for PWD. Future work should identify the most appropriate tools to measure these outcomes.
BACKGROUND:people with dementia (PWD), and their carers, face challenges with medicines management activities. As interventions to support medicines management for PWD are developed, consideration must be given to the outcomes chosen to measure their effectiveness. A Core Outcome Set (COS) is a minimum set of outcomes to be measured in all trials in a particular clinical area, which seeks to reduce heterogeneity of outcome reporting across trials. OBJECTIVE: to develop a COS for trials assessing the effectiveness of medicines management interventions for PWD in primary care. METHODS: a comprehensive list of outcomes was compiled through a systematic review and semi-structured interviews with PWD (n = 18), their carers (n = 15), community pharmacists (n = 15) and general practitioners (n = 15). These outcomes were rated by a Delphi panel (n = 52) on a nine-point Likert scale from 1 (limited importance) to 9 (critical) during three sequential rounds of questionnaire distribution. The Delphi panel comprised participants with expertise in dementia and medicines management, including academics and healthcare professionals. An outcome was eligible for inclusion in the COS if ≥70% of participants rated it critical and <15% of participants rated it of limited importance. RESULTS: twenty-nine outcomes identified from the systematic review and stakeholder interviews were presented to the Delphi panel. Consensus was reached on 21 outcomes, of which the 7 most highly rated were recommended for inclusion in the COS. CONCLUSION: this study used robust methodology to develop a COS for medicines management interventions for PWD. Future work should identify the most appropriate tools to measure these outcomes.
Authors: Rineke Gordijn; Martina Teichert; Melianthe P J Nicolai; Henk W Elzevier; Henk-Jan Guchelaar; Carmel M Hughes Journal: Sex Med Date: 2021-10-07 Impact factor: 2.491